What Are the CDE Clinical Trial Requirements for Foreign Sponsors in China?

1. The CDE and China’s Clinical Trial Regulatory Framework

The Center for Drug Evaluation (CDE), operating under the National Medical Products Administration (NMPA), is China’s equivalent of the FDA’s Center for Drug Evaluation and Research (CDER). Since China joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in 2017, the CDE has progressively aligned its clinical trial requirements with international standards, though important China-specific requirements remain. The CDE is responsible for reviewing all clinical trial applications, new drug applications, and post-approval changes for pharmaceutical products in China.

Foreign sponsors face a regulatory environment that has undergone rapid transformation over the past five years. The Drug Administration Law (2019 revision) and subsequent implementing regulations established a more streamlined clinical trial approval system, while the adoption of ICH guidelines has reduced, but not eliminated, the gap between Chinese and international requirements. The number of clinical trials conducted in China has grown substantially, with China now accounting for approximately 15% of global clinical trial activity, up from less than 5% a decade ago.

For foreign sponsors planning to conduct clinical trials in China, understanding the CDE’s requirements is essential for trial success. China’s vast patient population, rapidly developing clinical trial infrastructure, and increasingly efficient regulatory processes make it an attractive destination for clinical research, but the regulatory pathway requires careful navigation. The CDE has significantly expanded its review staff in recent years, adding over 500 new reviewers since 2020 to handle the growing volume of applications.

2. IND Application Requirements for Foreign Sponsors

The Investigational New Drug (IND) application is the key regulatory submission that foreign sponsors must file with the CDE before initiating any clinical trial in China. The IND dossier is submitted through the CDE’s online submission portal and must include several comprehensive sections covering all aspects of the drug’s quality, safety, and proposed clinical use.

2.1 General Administrative Documentation

The administrative section of the IND must include a cover letter specifying the drug type, trial phase, and indication; a letter of authorization from the foreign sponsor to the China-based legal representative or agent (if the sponsor does not have a legal entity in China); marketing authorization evidence from other jurisdictions (if applicable); the manufacturing license of the drug substance and product manufacturing facilities; and a Certificate of Pharmaceutical Product (CPP) if the drug is already approved in another jurisdiction. These documents establish the legal standing of the foreign sponsor and the regulatory status of the drug in other markets.

2.2 CMC (Chemistry, Manufacturing, and Controls) Dossier

The CMC section must describe the drug substance and drug product in detail, including structural characterization and physicochemical properties; the manufacturing process and process controls; specifications and analytical methods; stability data under ICH-recommended conditions; and container closure system information. The CDE requires CMC data that supports the proposed clinical trial duration and dosing regimen. For early-phase trials, the CMC requirements are typically less stringent than for marketing authorization applications, but the CDE still expects a comprehensive quality package. Foreign sponsors should note that the CDE has specific expectations for impurity profiling and genotoxic impurity assessment that may differ from FDA or EMA requirements.

2.3 Pharmacology and Toxicology Dossier

The preclinical package must demonstrate adequate safety for human trials and includes primary pharmacodynamics studies demonstrating the drug’s mechanism of action; secondary pharmacodynamics and safety pharmacology assessments (cardiovascular, respiratory, and central nervous system); pharmacokinetics including absorption, distribution, metabolism, and excretion (ADME) studies; toxicology including single-dose, repeat-dose, genotoxicity, reproductive toxicity, and carcinogenicity studies as appropriate; and local tolerance studies for injectable or topical formulations. The CDE generally accepts ICH-compliant preclinical studies conducted outside China, provided the studies were performed at GLP-certified facilities. However, for certain classes of drugs such as biologics, gene therapies, and cell therapies, the CDE may request bridging toxicology studies in Chinese-specific animal models if there are known ethnic differences in drug metabolism.

2.4 Clinical Study Protocol and Investigator’s Brochure

The clinical protocol must clearly describe trial objectives and endpoints; subject selection criteria (inclusion/exclusion); treatment regimen and dose rationale; study design including randomization, blinding, and control group specifications; the statistical analysis plan; safety monitoring plan; and data management and quality assurance procedures. The Investigator’s Brochure (IB) must be comprehensive and include all relevant preclinical and clinical data. For foreign sponsors submitting an IB developed outside China, the CDE accepts ICH-compliant IBs but may request China-specific data or analyses where relevant.

3. CDE Review Timeline and Process

The CDE operates on a statutory review timeline with specific milestones. The pre-submission meeting (optional but recommended) takes place 30-60 days before submission and provides CDE feedback on trial design, CMC strategy, and data requirements. After submission, IND acceptance takes 3-5 business days for a formal compliance check. The technical review period is 60 working days under the silent approval system. During this period, the CDE may issue questions and clarifications requiring additional data, which stops the clock. The final decision is issued within 60 working days. Ethics committee approval runs concurrently or sequentially depending on the trial type and hospital requirements.

The critical feature of China’s IND system is the “silent approval” mechanism: if the CDE does not issue any questions or objections within 60 working days of receiving a complete submission, the sponsor may proceed with the trial. This is similar to the Australian CTN scheme and provides regulatory certainty for trial planning. For priority drugs, including innovative drugs, drugs for life-threatening diseases, and drugs included in the breakthrough therapy designation program, the CDE may expedite review with a target of 40 working days. Foreign sponsors should request priority review status when the drug qualifies, as this can significantly reduce the overall timeline.

4. Good Clinical Practice (GCP) Compliance Requirements

China’s GCP standards have been updated to align with ICH E6 (R3), which was adopted by the CDE in 2025-2026. Clinical trials in China must be conducted at GCP-certified hospitals that have been accredited by the NMPA. As of 2026, China has over 1,000 GCP-certified trial sites across all provinces, with the highest concentration in Beijing, Shanghai, Guangzhou, and Chengdu. All trial protocols must receive ethics committee approval from the institutional review board (IRB) at each participating hospital. China has moved toward a centralized ethics review system for multi-center trials, where a lead IRB provides the primary review and participating sites accept the decision.

Informed consent forms must be provided in Chinese and must include all elements required under Chinese GCP. For illiterate subjects, the consent process must involve a legally acceptable representative and an impartial witness. The consent form must clearly describe compensation for trial-related injuries, which is a legal requirement under Chinese law. One of the most significant China-specific requirements for foreign sponsors is compliance with the Regulations on Human Genetic Resources Management (HRML). Any clinical trial involving the collection, storage, or transfer of human genetic material from Chinese subjects requires pre-approval from the Ministry of Science and Technology (MOST) before sample collection begins, international cooperation approval if foreign entities are involved, recording of data with MOST for certain categories, and approval for sample export if samples will be analyzed outside China. The HRML approval process adds 3-6 months to trial timelines.

5. Multi-Regional Clinical Trials (MRCT) for Foreign Sponsors

Foreign sponsors can include China in multi-regional clinical trials (MRCTs) under the ICH E17 framework. China accepts complete clinical data packages from foreign trials as supporting evidence for IND applications. For drugs that have already completed Phase I trials outside China, foreign sponsors can apply for a “global simultaneous development” pathway that allows China to join the global Phase II or Phase III program directly, without repeating earlier phases. For MRCTs that include China sites, the CDE expects a sufficient number of Chinese subjects to support a China-specific subgroup analysis, evidence of consistency between Chinese and global populations in terms of efficacy and safety, pharmacokinetic data in Chinese subjects, and consideration of ethnic factors in dose selection including body weight, genetic polymorphisms, dietary interactions, and concurrent medication patterns.

Foreign sponsors should conduct an ethnic sensitivity analysis to determine whether the drug is likely to exhibit significant ethnic differences in safety or efficacy. The ICH E5 (R1) framework provides guidance on intrinsic (genetic, physiologic) and extrinsic (cultural, environmental) ethnic factors. Drugs with high ethnic sensitivity may require more extensive China-specific clinical data, including dedicated Phase I PK studies in Chinese healthy volunteers before proceeding to Phase II or III in China.

6. Post-Approval Requirements for Foreign Sponsors

After receiving IND approval and completing the trial, foreign sponsors must comply with ongoing requirements including trial registration in the Chinese Clinical Trial Registry (ChiCTR) before enrollment of the first subject, annual Development Safety Update Reports (DSURs) submitted to the CDE, serious adverse event (SAE) reporting to the CDE within 7 days (fatal/life-threatening) or 15 days (other serious), trial completion reports submitted within 12 months of completion, and protocol amendments submitted for CDE review and approval before implementation. These post-approval obligations mirror international standards but have China-specific formatting and submission requirements that foreign sponsors must understand.

7. Common Pitfalls for Foreign Sponsors

Many foreign sponsors underestimate the variability in site capabilities across Chinese hospitals. Site qualification visits should assess patient volume, investigator experience, GCP compliance history, and infrastructure including laboratory capabilities and data management systems. Human genetic resource management applications are often underestimated in terms of preparation time and regulatory complexity. The accuracy of translated clinical documents is critical for CDE acceptance, as the CDE has been known to reject submissions with translation errors or inconsistent terminology. Finally, China’s Personal Information Protection Law (PIPL), effective since 2021, imposes strict requirements on the collection and processing of personal data, including health data from clinical trial subjects. Foreign sponsors must ensure compliance with PIPL, including obtaining separate consent for data processing and implementing appropriate data security measures.

8. Conclusion

The CDE’s clinical trial requirements for foreign sponsors have become increasingly aligned with international standards since China joined the ICH, yet important China-specific requirements remain. The key success factors for foreign sponsors include thorough preparation of the IND dossier, early engagement with the CDE through pre-submission meetings, proactive compliance with HRML requirements, and careful site selection and monitoring. China’s clinical trial environment continues to evolve rapidly, and foreign sponsors should monitor regulatory updates from the CDE and NMPA, particularly regarding the ongoing implementation of ICH guidelines, changes to the HRML framework, and updates to the GCP standards. Engaging experienced local regulatory and clinical operations partners is strongly recommended for successful trial execution in China.